AGN - Why 2020 Should Be the Biggest Year Yet for CRISPR Gene-Editing Stocks
Has there been a lot of hype about CRISPR gene editing? Absolutely. But while the hype might have been overdone in some cases, the reality is that there's significant potential for CRISPR (which stands for "clustered regularly interspaced short palindromic repeats") to transform the way many diseases are treated.
2019 has been an important year for the top CRISPR gene-editing stocks with the first human clinical studies cranking up. CRISPR Therapeutics (NASDAQ: CRSP) has been the biggest winner -- mainly because those studies were for its lead pipeline candidate. However, Editas Medicine (NASDAQ: EDIT) and Intellia Therapeutics (NASDAQ: NTLA) have also racked up nice year-to-date gains.
But as Bachman-Turner Overdrive sang, "You ain't seen nothing yet." Here's why 2020 should be the biggest year so far for CRISPR gene-editing stocks.